A single dose, parallel group study to evaluate pharmacokinetics of isavuconazole administered as prodrug isavuconazonium sulfate in healthy volunteers with mild and moderate hepatic impairment due to hepatitis B or C

Trial Profile

A single dose, parallel group study to evaluate pharmacokinetics of isavuconazole administered as prodrug isavuconazonium sulfate in healthy volunteers with mild and moderate hepatic impairment due to hepatitis B or C

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Isavuconazonium (Primary) ; Isavuconazonium (Primary)
  • Indications Aspergillosis; Candidiasis; Zygomycosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 Oct 2017 New trial record
    • 01 May 2016 Results (n=96) of development and validation of population pharmacokinetic model published in the Antimicrobial Agents and Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top